Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  title={Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.},
  author={Hartmut D{\"o}hner and Elihu H Estey and David Grimwade and Sergio Amadori and Frederick R. Appelbaum and Thomas Büchner and Herv{\'e} Dombret and Benjamin L. Ebert and Pierre Fenaux and Richard A. Larson and Ross L. Levine and Francesco Lo‐Coco and Tomoki Naoe and Dietger Niederwieser and Gert Jan Ossenkoppele and Miguel Angel Sanz and Jorge Sierra and Martin S. Tallman and Hwei-Fang Tien and Andrew H. Wei and Bob L{\"o}wenberg and Clara Derber Bloomfield},
  volume={129 4},
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. [] Key Method The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Figures and Tables from this paper

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

This review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder APL differentiation syndrome, QT prolongation, and other all-trans retinoic acid- and ATO-related toxicities.

The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know.

  • D. Arber
  • Medicine, Biology
    Seminars in hematology
  • 2019
This review summarizes the WHO approach as well as the priority of specific features for disease classification of acute myeloid leukemia, including AML with myelodysplasia-related changes, and changes to specific categories.

A summary of the molecular testing recommended in acute myeloid leukemia

The molecular testing currently recommended in AML is summarized and new mutations that may have prognostic value and clinical application in the near future are introduced.

Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours

Advances in target-based therapy for AML are reviewed focusing on their mechanism of action, examining the intracellular events and pathways, and the results from published clinical trials, to improve the therapeutic armamentarium available.

Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus

An Iberian expert panel has reviewed the recent advances in the management of R/R AML with the aim to develop updated evidence and expert opinion-based recommendations.

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

Novel prognostic models using the biomarkers from the guidelines, age, performance status and select transcript biomarkers demonstrate the need for additional prognostic factors, including age, to improve risk stratification.

Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

A concise summary of current evidence regarding the relevance of NGS for the diagnosis, risk stratification, treatment planning and response assessment in AML, including minimal residual disease (MRD) guided approaches is provided.

The face of remission induction

Seven new agents have been approved for the treatment of AML since 2017, all of which are directed toward a specific molecular subtype or patient population, and the role of these novel therapies in the remission induction setting is discussed.

Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

There is increasing awareness that AML is a widely heterogeneous disease, not only based on clinical characteristics and demographics of the patients the authors treat but also based on the genomics of the disease, which has allowed the field to move away from a "one-size-fits-all" approach in newly diagnosed AML to a more thoughtful, individualized approach based on these factors.

How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

Using a selection of real‐life examples, how molecular monitoring can be used to refine clinical decision‐making and to personalise treatment in patients with AML with nucleophosmin mutations, core binding factor translocations and other fusion genes is shown.



Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

This review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment.

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

The ELN classification clearly separates the genetic groups by outcome, supporting its use for risk stratification in clinical trials.

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.

In the 2008 WHO classification scheme, FAB subclassification does not provide prognostic information for "AML, NOS" cases if data on NPM1 and CEBPA mutations are available.

MRD in AML: it is time to change the definition of remission.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.

Acute myeloid leukemia.

Recent advances in understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions are reviewed, including the advanced myelodysplastic syndromes (MDS), while Drs.

New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.

The recently approved agents in AML are discussed, the rationale behind their development and the trials that served as the basis for their approval, and the implications of their introduction into the treatment armamentarium are discussed.

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

The detection of persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples was associated with a significantly increased risk of relapse, and reduced overall survival.

How I treat the older patient with acute myeloid leukemia.

The dilemmas in tailoring treatment selection in this category of patients with AML are the central theme in this discussion.